The estimated Net Worth of Laura L. Johnson is at least $560 dollars as of 30 May 2018. Laura Johnson owns over 500 units of Odonate Therapeutics Inc stock worth over $560 and over the last 11 years Laura sold ODT stock worth over $0.
Sign up
Laura Johnson ODT stock SEC Form 4 insiders trading
Laura has made over 2 trades of the Odonate Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Laura exercised 500 units of ODT stock worth $3,000 on 30 May 2018.
The largest trade Laura's ever made was exercising 10,000 units of Odonate Therapeutics Inc stock on 29 December 2017 worth over $89,000. On average, Laura trades about 583 units every 8 days since 2013. As of 30 May 2018 Laura still owns at least 500 units of Odonate Therapeutics Inc stock.
You can see the complete history of Laura Johnson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Laura Johnson's mailing address?
Laura's mailing address filed with the SEC is 6, 10182 Telesis Ct, San Diego, CA 92121, USA.
Insiders trading at Odonate Therapeutics Inc
Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis et Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.
What does Odonate Therapeutics Inc do?
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
What does Odonate Therapeutics Inc's logo look like?
Complete history of Laura Johnson stock trades at La Jolla Pharmaceutical Co et Odonate Therapeutics Inc
Odonate Therapeutics Inc executives and stock owners
Odonate Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Joseph O'Connell,
Chief Medical Officer -
John Lemkey,
Chief Operating Officer -
Dr. Joseph P. O'Connell M.D.,
Chief Medical Officer -
Craig Johnson,
Independent Director -
Laura Douglass,
Independent Director -
Robert Rosen,
Director -
Kevin Tang,
Chairman of the Board, Chief Executive Officer -
Aaron Davis,
Independent Director -
Michael Hearne,
Chief Financial Officer -
Kim Ma,
Sr. VP of Clinical Operations -
Jennifer Schroeder,
Sr. VP of Program Management & Technology -
Tracey McKennon,
Sr. VP of Quality Assurance -
Stewart M. Kroll,
Chief Devel. Officer -
Thomas Wei,
Chief Scientific Officer -
Dr. Steven S. Pfeiffer Ph.D.,
Sr. VP of Technical Operations -
Ryan Cole,
Sr. VP of Operations -
Jeff L Vacirca,
Director -
Capital, Llc Boxer Asset Ma...,
-
George F Tidmarsh,
Director -
Robert D Millham,
Chief Operating Officer -
John G Lemkey,
Chief Operating Officer -
Laura L. Johnson,
Director -
Kevin Ctang Capital Partner...,
Chief Executive OfficerChief Operating OfficerChief Financial Officer -
Capital, Llc Boxer,
10% owner -
Kevin Ctang Capital Partner...,
Chief Executive OfficerChief Financial Officer -
Capital, Llc Eco R1,
10% owner